In terms of ccRCC treatment, GPx1 was used as a biomarker to judge the prognosis of ccRCC (146), but there have been no reports on the application of ferroptosis in clinical treatment over a wide range. Here, GPX1 is linked to nonpapillary renal cell carcinoma.